Neurogene offers a heavily favorable stated risk/reward against its analyst target and a stock holding above its 200-day moving average, but quality sits far below the minimum floor amid cash burn, the technical setup is overbought, short interest is elevated, and insiders have leaned bearish.
Thesis pillars
- Favorable Analyst Target Asymmetry→Stable
- Deeply Weak Quality Cash Burn→Stable
- Overbought Uptrend Above 200ma→Stable
- +2 more pillars — see the Why tab for full reasoning
Neurogene Inc. (NGNE) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $37.50: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality.
Neurogene is a clinical-stage biotechnology company developing gene therapies for rare neurological diseases using its EXACT transgene-regulation platform, which employs microRNA-based genetic circuits to precisely control transgene expression. Its lead and only clinical-stage... Read more
Sell if holding. Engine safety override at $37.50: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Neurogene Inc.
About Neurogene Inc.
Neurogene has raised approximately $552.1 million in aggregate net proceeds since its 2018 founding and reported an accumulated deficit of $352.6 million and $269.0 million of cash, cash equivalents and short-term investments as of December 31, 2025, funding its EXACT transgene-regulation platform and lead gene-therapy candidate NGN-401. NGN-401 is now in Phase 3 development (the Embolden registrational trial) for Rett syndrome after receiving FDA Breakthrough Therapy designation in February 2026, building on earlier Fast Track and Regenerative Medicine Advanced Therapy designations. The company discontinued its only other clinical program, NGN-101 for CLN5 Batten disease, in November 2024 after the FDA denied a streamlined-pathway RMAT application.
Neurogene generates no product revenue and funds its entire operation, platform development, preclinical studies, clinical trials and general administrative costs, through equity issuances, with net losses of $90.4 million in 2025 and $75.1 million in 2024. Its lead program, NGN-401, pairs the full-length MECP2 gene with the company's proprietary EXACT technology, a microRNA-based genetic circuit designed to precisely tune transgene expression and avoid toxicity that has limited earlier gene-replacement approaches to Rett syndrome; the Embolden registrational trial is evaluating a single 1E15 vg dose in 20 female Rett syndrome patients, with enrollment complete and more than half of participants dosed as of early 2026. The filing notes one non-disease-modifying treatment for Rett syndrome is currently approved, without naming the product, framing NGN-401 as a potential first disease-modifying option if Embolden succeeds. Neurogene's discovery engine, built with the University of Edinburgh under a collaboration agreement extended through December 2026, also supports earlier-stage preclinical programs targeting other neurological conditions.
Show full overview
Neurogene's value is concentrated almost entirely in a single dosing regimen of a single gene therapy: after discontinuing NGN-101 in November 2024, NGN-401 became the company's only clinical-stage program, and the Embolden trial's 35% response-rate threshold, 7 of 20 patients, across a fixed 1E15 vg dose determines whether the single-arm, baseline-controlled study succeeds. This concentration is amplified by manufacturing risk, since all clinical-grade NGN-401 used in both the completed Phase 1/2 trial and the ongoing Embolden trial has been produced at Neurogene's own Houston, Texas facility, meaning any disruption there could affect drug supply for the company's sole active clinical program simultaneously.
See also: Healthcare · Biotechnology
From Neurogene Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Neurogene Inc.
Latest news
- NEWS Neurogene Prices $125M Public Offering At $30/Share, $29.999999 Pre‑Funded Warrants — benzinga Jul 1, 2026 negative
- NEWS Neurogene Reveals Proposed Public Offering; No Size Disclosed — benzinga Jun 30, 2026 negative
- NEWS Neurogene Announces Updated Data From Phase 1/2 Clinical Trial Evaluating NGN-401 Gene Therapy For Treatment Of Females — benzinga Jun 29, 2026 positive
Generated 2026-07-08T23:03:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineNGN-401 (Rett syndrome)10-K Item 1: 'Our most advanced program, NGN‑401, is in Phase 3 clinical development for the treatment of Rett syndrome.'
Material Events(8-K, last 90d)
- 2026-04-20Item 5.02LOWOn April 20, 2026 Neurogene's Board expanded to seven directors and appointed Christine Mikail, the company's President and CFO, to the newly created seat as a Class II director through the 2028 annual meeting. Routine board expansion; no departure involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $37.50: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 28%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $35.56. Score 5.5/10, moderate confidence.
Take-profit target: $70.47 (+84.3% upside). Prior stop was $35.56. Stop-loss: $35.56.
Concentration risk — Pipeline: NGN-401 (Rett syndrome); Quality below floor (1.6 < 4.0).
Neurogene Inc. trades at a P/E of N/A (forward -6.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
15 analysts cover NGNE with a consensus score of 4.3/5. Average price target: $81.
What does Neurogene Inc. do?Neurogene is a clinical-stage biotechnology company developing gene therapies for rare neurological diseases using its...
Neurogene is a clinical-stage biotechnology company developing gene therapies for rare neurological diseases using its EXACT transgene-regulation platform, which employs microRNA-based genetic circuits to precisely control transgene expression. Its lead and only clinical-stage program, NGN-401, is in Phase 3 development (the Embolden trial) for Rett syndrome, having received FDA Breakthrough Therapy designation in February 2026 after earlier Fast Track and RMAT designations. The company has no approved products, reported a $552.1 million cumulative capital raise since 2018, and discontinued it